Harvoni U.S. Sales Dip Reflects Progress In Treating Sickest Patients, Gilead Says
This article was originally published in The Pink Sheet Daily
Overall HCV sales continue to grow at Gilead despite some softness in the U.S. market – one near-term positive is Sovaldi should launch in the U.K. soon, followed quickly by Harvoni.
Register for our free email digests: